Pfizer Inc. signaled it remains firmly footed in the obesity space, announcing on 11 July that it has selected a once-daily, modified-release formulation of its oral glucagon-like peptide-1 (GLP-1) receptor agonist danuglipron to advance in development.
Key Takeaways
- The once-daily formulation of the GLP-1 agonist danuglipron uses modified release.
The decision is based on the results of an ongoing pharmacokinetic and safety study evaluating immediate- and modified-release formulations of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?